These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3091280)

  • 1. Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.
    Rutty CJ; Judson IR; Abel G; Goddard PM; Newell DR; Harrap KR
    Cancer Chemother Pharmacol; 1986; 17(3):251-8. PubMed ID: 3091280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity.
    Judson IR; Rutty CJ; Abel G; Graham MA
    Br J Cancer; 1986 May; 53(5):601-6. PubMed ID: 3087399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse.
    Rutty CJ; Newell DR; Muindi JR; Harrap KR
    Cancer Chemother Pharmacol; 1982; 8(1):105-11. PubMed ID: 6807560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice.
    Broggini M; Rossi C; Colombo T; D'Incalci M
    Cancer Treat Rep; 1982 Jan; 66(1):127-33. PubMed ID: 6796267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.
    Boven E; Nauta MM; Schlüper HM; Erkelens CA; Pinedo HM
    Cancer Chemother Pharmacol; 1986; 18(2):124-8. PubMed ID: 3098444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-(Hydroxymethyl) melamines.
    Coley HM
    Gen Pharmacol; 1997 Feb; 28(2):177-82. PubMed ID: 9013191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
    Judson IR; Calvert AH; Rutty CJ; Abel G; Gumbrell LA; Graham MA; Evans BD; Wilman DE; Ashley SE; Cairnduff F
    Cancer Res; 1989 Oct; 49(19):5475-9. PubMed ID: 2670205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of hexamethylmelamine and pentamethylmelamine in mice.
    Broggini M; Colombo T; D'Incalci M; Donnelli MG; Gescher A; Garattini S
    Cancer Treat Rep; 1981; 65(7-8):669-72. PubMed ID: 6788370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the stability of trimelamol, a carbinolamine-containing antitumor drug.
    Jackson C; Crabb TA; Gibson M; Godfrey R; Saunders R; Thurston DE
    J Pharm Sci; 1991 Mar; 80(3):245-51. PubMed ID: 2051341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analogues of hexamethylmelamine. The anti-neoplastic activity of derivatives with enhanced water solubility.
    Cumber AJ; Ross WC
    Chem Biol Interact; 1977 Jun; 17(3):349-57. PubMed ID: 407012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N2,N4,N6-tri(hydroxymethyl)-N2,N4,N6-trimethylmelamine (trimelamol) is an efficient DNA cross-linking agent in vitro.
    Jackson C; Hartley JA; Jenkins TC; Godfrey R; Saunders R; Thurston DE
    Biochem Pharmacol; 1991 Nov; 42(11):2091-7. PubMed ID: 1958227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-pass metabolism of pentamethylmelamine in the rat liver.
    Klippert PJ; Hulshoff A; Hofman GA; Noordhoek J
    Cancer Res; 1985 Mar; 45(3):983-6. PubMed ID: 3918792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pentamethylmelamine: review of an aqueous analog of hexamethylmelamine.
    Foster BJ; Clagett-Carr K; Hoth D; Leyland-Jones B
    Cancer Treat Rep; 1986 Mar; 70(3):383-9. PubMed ID: 3082512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical development of the anti-tumour agent CB 7646, bis N-(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamol.
    Coley HM; Jarman M; Brooks N; Kubota T; Goddard PM; Jones M; Lee N; Owens MD; Halbert GW; Judson IR
    Int J Cancer; 1996 Nov; 68(3):356-63. PubMed ID: 8903478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies of the mode of action of antitumour triazenes and triazines-V. The correlation of the in vitro cytotoxicity and in vivo antitumour activity of hexamethylmelamine analogues with their metabolism.
    Ross D; Langdon SP; Gescher A; Stevens MF
    Biochem Pharmacol; 1984 Apr; 33(7):1131-6. PubMed ID: 6424683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption and metabolism of hexamethylmelamine and pentamethylmelamine in rat everted perfused gut segments: correlation with in-vivo data.
    Borm PJ; Frankhuyzen-Sierevogel AC; Weller EB; Noordhoek J
    J Pharm Pharmacol; 1985 Sep; 37(9):629-36. PubMed ID: 2867183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effect of trimelamol against human breast carcinoma xenografts in nude mice.
    Yamada Y; Kubota T; Hoshiya Y; Asanuma F; Koh J; Kitajima M; Coley H; Judson I
    Oncol Rep; 1996 Jul; 3(4):613-7. PubMed ID: 21594422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of pentamethylmelamine in humans.
    Benvenuto JA; Stewart DJ; Benjamin RS; Loo TL
    Cancer Res; 1981 Feb; 41(2):566-9. PubMed ID: 6778609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution, metabolism, and irreversible binding of hexamethylmelamine in mice bearing ovarian carcinoma.
    Garattini E; Colombo T; Donelli MG; Catalani P; Bianchi M; D'Incalci M; Pantarotto C
    Cancer Chemother Pharmacol; 1983; 11(1):51-5. PubMed ID: 6411375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a parenteral formulation of trimelamol, a synthetic S-triazine carbinolamine-containing cytotoxic agent.
    Gibson M; Denham AJ; Taylor PM; Payne NI
    J Parenter Sci Technol; 1990; 44(6):306-13. PubMed ID: 2277318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.